# SP-002

Source: https://onco.cc/drugs/sp-002/  
OnCo record `sp-002` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SP-002 is an experimental gene therapy: replication-deficient adenovirus serotype 5 vector, injected into the tumour from Stamford Pharmaceuticals, in phase 2 trials for basal cell carcinoma and cutaneous squamous cell carcinoma.

## Summary

SP-002 (ASN-002) is a gene therapy: replication-deficient adenovirus serotype 5 vector, injected into the tumour from Stamford Pharmaceuticals, with Ascend Biopharmaceuticals Ltd as partner. A replication-deficient adenovirus-5 vector carrying the human interferon gamma gene, injected into the tumour so that infected cells make interferon gamma locally. Its furthest stage is phase 2, for basal cell carcinoma and cutaneous squamous cell carcinoma. ClinicalTrials.gov registers it in 2 studies linked below. Phase 2 with vismodegib in locally advanced BCC recruiting (NCT06344052); phase 2a ASN-002-003 in multiple BCCs completed with positive results announced January 2025 (NCT04416516). Company plans phase 2/3 in H/M-zone nodular BCC in 2027 and has an open IND, phase 1/2-ready, for cutaneous SCC. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: ASN-002
- Tags: pipeline; ctgov-ingest
- Code: SP-002
- Modality: Gene therapy: replication-deficient adenovirus serotype 5 vector, injected into the tumour
- Mechanism: A replication-deficient adenovirus-5 vector carrying the human interferon gamma gene, injected into the tumour so that infected cells make interferon gamma locally.

## Sources

- Stamford Pharmaceuticals: stamfordpharmaceuticals.com: https://stamfordpharmaceuticals.com/
- Stamford Pharmaceuticals: stamfordpharmaceuticals.com: https://stamfordpharmaceuticals.com/
- Stamford Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06344052
- ClinicalTrials.gov: trials of SP-002: https://clinicaltrials.gov/search?intr=SP-002

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- companies: [Stamford Pharmaceuticals](https://onco.cc/companies/stamford-pharmaceuticals/)
- trials: [Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor](https://onco.cc/trials/nct04416516/), [To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma](https://onco.cc/trials/nct06344052/)

---
JSON: https://onco.cc/api/v1/entities/sp-002.json